Longevity and Metabolic Research Compounds: An Overview

Aging research is organized less around a single target than around a set of observed processes. The hallmarks of aging framework, first proposed in 2013 and revised in 2023, groups these into categories including genomic instability, telomere attrition, epigenetic alteration, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, and cellular senescence. Compounds studied in this space generally target one of these processes rather than aging as such.

That structure creates a recurring interpretive problem. Most published results in this field are biomarker results: a compound shifts a measurement associated with aging. A biomarker moving is not the same as a functional outcome improving, and it is very far from a lifespan or healthspan effect. The field's own gold standard, the National Institute on Aging Interventions Testing Program, runs lifespan studies in genetically heterogeneous mice at multiple independent sites specifically because single-site rodent lifespan results have proven unreliable, and the majority of compounds tested there have shown no lifespan effect.

Everything below is described at the level of the published literature. All compounds discussed are research compounds supplied for laboratory research use only. None are approved drugs or dietary supplements, and nothing here describes an effect in humans or any use in humans.

Nicotinamide adenine dinucleotide is not a peptide. It is a dinucleotide coenzyme, and it is included here because it sits at the center of the metabolic research this class is organized around. Its established biochemistry is not in dispute: it cycles between oxidized NAD+ and reduced NADH as the principal electron carrier in central metabolism, participating in glycolysis, the citric acid cycle, and oxidative phosphorylation.

The reason it appears in aging research is its second role as a consumed substrate. Sirtuins, a family of NAD+-dependent deacylases implicated in metabolic regulation, consume NAD+ stoichiometrically. So do PARP enzymes involved in DNA damage response, and CD38, an NADase whose expression increases with age. Tissue NAD+ levels have been reported to decline with age across multiple species and tissues, and the hypothesis that this decline contributes to age-associated metabolic change has driven a large research program.

The clearest human data concerns precursors rather than NAD+ itself. Nicotinamide riboside and nicotinamide mononucleotide have been studied in human trials, and the consistent finding is that oral administration raises blood NAD+ metabolite levels. Functional endpoints have been much less consistent, with several well conducted trials reporting no significant effect on the physiological measures they were powered to detect. Raising the level is demonstrated. What raising the level accomplishes is not.

For laboratory handling, NAD+ is chemically distinct from the peptides in this group and less forgiving. It is hygroscopic, unstable in alkaline solution, and degrades in aqueous solution more readily than a typical peptide, so fresh preparation and cold, dry, dark storage of the dry material are the practical requirements.

MOTS-c, short for mitochondrial open reading frame of the 12S rRNA type-c, is a sixteen residue peptide encoded not in nuclear DNA but within the mitochondrial genome, in a short open reading frame inside the 12S ribosomal RNA gene. It belongs to a small class of mitochondrial-derived peptides identified over the past two decades, and its discovery is one of the more interesting findings in mitochondrial biology of that period.

Reported mechanistic work centers on metabolic regulation. Studies have described effects on the folate-methionine cycle and on downstream purine biosynthesis, with consequent activation of AMP-activated protein kinase, the cell's principal energy-sensing kinase. Separate work has reported that MOTS-c translocates to the nucleus under metabolic stress and associates with stress-responsive transcription factors, which would make it an unusual example of a mitochondrially encoded peptide with a nuclear regulatory role.

The animal literature includes rodent studies reporting effects on insulin sensitivity, adiposity in diet-induced obesity models, and exercise capacity in aged mice. Human data exists but is observational in character: circulating MOTS-c levels have been measured in human subjects and reported to increase with exercise, and levels have been compared across metabolic phenotypes. Those are association studies. There are no substantial human interventional trials establishing what administering MOTS-c does.

Epithalon, also written epitalon, is a tetrapeptide with the sequence Ala-Glu-Asp-Gly. It emerged from a research program in St. Petersburg associated with Vladimir Khavinson, developed as a synthetic analogue of a peptide preparation derived from pineal gland extract.

The published claims center on telomerase. Cell culture work from that program reported induction of telomerase catalytic subunit expression and telomere elongation in cultured human somatic cells, and associated publications reported effects on lifespan and tumor incidence in rodent models along with results from human cohorts described as long-term follow-up studies.

The methodological situation requires plain statement. A large majority of the published work on Epithalon originates from a single research program. Independent replication by unaffiliated laboratories is very limited. Several of the human studies attributed to it have been described in the broader literature as lacking the design features, randomization, blinding, prespecified endpoints, and reporting standards that would be expected for the conclusions drawn. This does not establish that the findings are wrong, but it does mean the evidence base rests substantially on one source, which is a materially weaker position than a finding replicated across independent groups.

The telomerase hypothesis also carries an unresolved tension. Telomerase activity is a defining feature of most cancer cells, so interventions that increase telomerase expression in somatic cells raise questions any serious program in this area has to address directly. As a research compound, Epithalon is a short, highly soluble, cysteine-free tetrapeptide with no unusual handling difficulty.

SS-31 is a Szeto-Schiller tetrapeptide, one of a series of small aromatic-cationic peptides designed to concentrate in mitochondria. Its clinical development name is elamipretide. Among the compounds in this article it is unusual in one important respect: it has a genuine human clinical trial record.

Its mechanism is more specifically characterized than most in this class. SS-31 binds cardiolipin, a phospholipid essentially unique to the inner mitochondrial membrane and essential to the organization of the electron transport chain supercomplexes. By associating with cardiolipin, the peptide is proposed to stabilize cristae architecture and improve the efficiency of electron transport, reducing electron leak and consequent reactive oxygen species generation. This is a structural mechanism rather than an antioxidant one in the conventional sense, and it is supported by biophysical work on the peptide-lipid interaction.

The clinical record is instructive precisely because it is mixed. Elamipretide has been evaluated in humans in primary mitochondrial myopathy, in Barth syndrome, and in ophthalmic and cardiac indications. Several of those programs did not meet their primary endpoints, including a phase 3 trial in primary mitochondrial myopathy. Others reported signals on secondary measures. The compound has been the subject of ongoing regulatory review for a rare disease indication. The honest summary is that it is a well characterized molecule with a real and unresolved clinical development history, which places it in a different evidentiary category from every other compound discussed here.

SS-31 is the useful case study in this group: a defined molecular target, biophysical evidence for the interaction, animal data, and human trials that nonetheless did not produce a clean result. That sequence is normal in drug development and worth holding in mind when reading about compounds that have not reached the same stage.

Incretin receptor signaling is one of the most active areas in metabolic research. The endogenous incretins, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are gut-derived peptide hormones that potentiate glucose-dependent insulin secretion, and their receptors, along with the glucagon receptor, are class B G protein-coupled receptors with overlapping downstream signaling. Research has moved from single-receptor agonists toward multi-receptor agonists engineered to activate two or three of them with tuned relative potency.

That research direction is well documented in the peer-reviewed literature and in the clinical development record of several approved and investigational agents. What is important for a researcher to keep separate is that this literature describes specific, structurally characterized molecules with published sequences and published trial data. It does not transfer automatically to any other compound described as acting on the same pathway.

GLP-3R is supplied as a research compound. Publicly available characterization of it is limited, and there is no published human clinical data for it. Researchers should not assume equivalence to any clinically characterized incretin agent on the basis of pathway association, and should treat receptor selectivity, potency, and signaling bias as open questions to be established experimentally rather than assumed. Where a research program depends on identity, analytical confirmation of the material by mass spectrometry and purity determination by RP-HPLC is the appropriate starting point.

As with everything in this article, this compound is supplied for laboratory research use only and is not approved for any use in humans.

Longevity research attracts more overstatement than most areas of biology, and a few reading habits do most of the work of filtering it. Separate the evidence tiers every time: cell culture, invertebrate models, rodent models, human observational studies, and human interventional trials are five distinct levels, and a finding at one is not a finding at the next. Lifespan extension in yeast, worms, or flies has historically been a poor predictor of anything in mammals.

Watch for biomarker substitution. Much of this literature reports that a compound moved a measurement: a metabolite level, an expression profile, a methylation-based age estimate. Epigenetic age clocks in particular have become popular endpoints, and they are correlational instruments whose response to an intervention has not been shown to track functional outcome.

Finally, account for the material itself. Between-supplier differences in purity, impurity identity, counterion load, and net peptide content are real and rarely reported in published methods. When a result fails to replicate, the material is a legitimate candidate explanation alongside the biology.